— Know what they know.
Not Investment Advice

NGM NASDAQ

NGM Biopharmaceuticals, Inc.
1W: -1.3% 1M: +0.7% 3M: +14.9% 1Y: -60.8% 3Y: -94.5% 5Y: -89.5%
$1.54
Last traded 2024-04-08 — delisted
NASDAQ · Healthcare · Biotechnology · $128.5M mcap · 29M float · 3.36% daily turnover

📊 Key Metrics

TTM
$4M
Revenue
-92.0% YoY
$-140M
Net Income
+12.1% YoY
$-133M
Free Cash Flow
+8.8% YoY
-213.9%
Gross Margin
-17977.6%
Op. Margin
-16769.7%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-68.5%
ROA-58.7%
ROIC-8229.4%

Valuation

P/E-0.9
P/B0.9
EV/EBITDA0.5

Leverage

Debt/Equity0.00
Current Ratio7.79
Interest Cov.-38.0x

Quality Scores

Piotroski F3/9
Altman Z-4.79
Beneish M-19.90

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms